Allarity Therapeutics (ALLR) CFO awarded 150,000 restricted stock units

Rhea-AI Filing Summary

Ervin Jeffrey S reported acquisition or exercise transactions in this Form 4 filing.

Allarity Therapeutics, Inc. reported that its CFO, Jeffrey S. Ervin, received a grant of 150,000 shares of Common Stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he holds 150,000 shares directly.

The RSUs were granted on January 28, 2026 under Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan. They will vest in equal one-third installments on the first, second, and third anniversaries of the grant date, if he continues his relationship with the company through each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ervin Jeffrey S

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	150,000	$0.00	--

Holdings After Transaction: Common Stock — 150,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 150,000 shares Grant price per share: $0.00 per share Post-grant direct holdings: 150,000 shares +1 more

4 metrics

RSU grant size 150,000 shares Restricted stock units of Common Stock granted to CFO on January 28, 2026

Grant price per share $0.00 per share Stated price for the 150,000 RSUs

Post-grant direct holdings 150,000 shares Total Common Stock directly held by the CFO after the grant

Vesting structure One-third annually over three years RSUs vest on the first, second, and third anniversaries of the January 28, 2026 grant

Key Terms

restricted stock units, Amended and Restated 2021 Equity Incentive Plan, vest in equal one-third installments

3 terms

restricted stock units financial

"The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated 2021 Equity Incentive Plan financial

"granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan"

vest in equal one-third installments financial

"will vest in equal one-third installments on the first, second, and third anniversary of the grant"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ervin Jeffrey S

(Last) (First) (Middle)

C/O ALLARITY THERAPEUTICS, INC.

123 E TARPON AVE

(Street)

TARPON SPRINGS FLORIDA 34689

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allarity Therapeutics, Inc. [ ALLR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		150,000(1)	A	$0	150,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units, or RSUs, granted on January 28, 2026 pursuant to Allarity Therapeutics, Inc's Amended and Restated 2021 Equity Incentive Plan, will vest in equal one-third installments on the first, second, and third anniversary of the grant, subject to the Reporting Person's continued relationship with the Issuer through each such date.

	/s/ Jeffrey S. Ervin	04/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Allarity Therapeutics (ALLR) report for its CFO?

Allarity Therapeutics reported that CFO Jeffrey S. Ervin received 150,000 restricted stock units of Common Stock. The award was reported at a price of $0.00 per share and represents a compensation grant, increasing his directly held shares to 150,000 following the transaction.

How many shares did the Allarity Therapeutics CFO acquire in the latest Form 4 filing?

The CFO acquired 150,000 shares of Common Stock through a restricted stock unit grant. These RSUs were awarded on January 28, 2026 and are structured to vest over three years, subject to his continued relationship with Allarity Therapeutics during the vesting period.

What is the vesting schedule for the Allarity Therapeutics CFO’s 150,000 RSU grant?

The 150,000 restricted stock units will vest in three equal installments. One-third of the RSUs vest on each of the first, second, and third anniversaries of the January 28, 2026 grant date, conditional on the CFO maintaining his relationship with Allarity Therapeutics through each vesting date.

Under which plan were the Allarity Therapeutics CFO’s restricted stock units granted?

The restricted stock units were granted pursuant to Allarity Therapeutics, Inc.'s Amended and Restated 2021 Equity Incentive Plan. This plan provides equity-based compensation, and the CFO’s 150,000 RSUs are subject to time-based vesting over three years from the grant date.

What does the $0.00 price per share mean in the Allarity Therapeutics CFO’s RSU grant?

The $0.00 price per share indicates the CFO did not pay cash to receive the 150,000 restricted stock units. RSUs are typically granted as part of compensation, with value realized as they vest and convert into Common Stock, assuming the service-based vesting conditions are met.